ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
How long to delay orthopedic surgery for preoperative BHO using ABL remains unclear. MAIN FINDING: ABL results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis. ABL shows promise for preoperative BHO in elective orthopedic surgery patients, but further research is required. PURPOSES: This study aims to assess the early response to abaloparatide (ABL) in men and postmenopausal women with osteoporosis at high risk for fracture to inform its potential role in preoperative bone health optimization (BHO). We aim to assess changes in bone mineral density (BMD) by three months and early changes in bone turnover markers (BTMs).
methodsA post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed. The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine. BTMs P1NP and CTX were also assessed.
resultsAt 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively. In women, mean BMD percent increases at the same sites were 1.55 (0.28), 1.78 (0.21), and 4.42 (0.34) respectively. Compared with baseline, serum P1NP increased over threefold at 1 month in women and men.
conclusionSubcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk. Bone formation is increased at 1 month and sustained for 12 months. Further research is required to investigate the effectiveness of a three-month ABL treatment period on bone strength and osteoporosis-related surgical complications in elective orthopedic surgery patients.
Indexed as
Identifiers
42498818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.